Related Experiment Video
Updated: Aug 18, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer
Borut Kragelj1, Lijana Zaletel-Kragelj, Boris Sedmak
1Department of Radiation Therapy, Institute of Oncology, SI-1000 Ljubljana, Slovenia. bjragelj@onko-i.si
Abstract:
Concurrent vinablastine-based radiochemotherapy was evaluated in 84 bladder-cancer patients. It was effective in more than half: tumour-specific survival (51% 9-year), local control rate (55% 9-year). The drawback was the impaired function of the bladder (9-year prevalence SOMA G3-4 symptoms: 66%), indicating the need for treatment aimed at reducing chronic morbidity.
